Cross-Protection of Mice Immunized With GM-CSF/IL-12–Transfected Tumor Cells From Challenge With MPC11 Cells or MDR Variants
| Mice . | Challenge . | |
|---|---|---|
| MPC11 . | MPC11Dox10* . | |
| Naive | 15/15† | 10/10 |
| Immunized with | ||
| MPC11 | ||
| Irradiated cells | 14/15 | 10/10 |
| Irradiated, GM-CSF/IL-12–transfected cells | 0/15‡ | 1/10‡ |
| MPC11 Dox 10 | ||
| Irradiated cells | 13/15 | 15/15 |
| Irradiated, GM-CSF/IL-12–transfected cells | 1/15‡ | 0/15‡ |
| Mice . | Challenge . | |
|---|---|---|
| MPC11 . | MPC11Dox10* . | |
| Naive | 15/15† | 10/10 |
| Immunized with | ||
| MPC11 | ||
| Irradiated cells | 14/15 | 10/10 |
| Irradiated, GM-CSF/IL-12–transfected cells | 0/15‡ | 1/10‡ |
| MPC11 Dox 10 | ||
| Irradiated cells | 13/15 | 15/15 |
| Irradiated, GM-CSF/IL-12–transfected cells | 1/15‡ | 0/15‡ |
The results with MPC11Dox10-1 and MPC11Dox10-2 sublines were similar; therefore, cumulative data of three experiments obtained with both sublines (designated as MPC11Dox10) are presented.
Number of mice that developed tumor/number of mice challenged.
P < .001 (by χ2 criterion) as compared with naive mice or animals immunized with irradiated cells.